New Study provides Vaginal Atrophy Global Pipeline Overview and Therapeutic Landscape

Albany, New York, December 9, 2016: Market Research Hub has highlighted the pipeline landscape of vaginal atrophy therapeutics in a new report added to its repository. The main purpose of this study is to provide an assessment of the various pipeline therapeutics for the disease. The report, titled ‘Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2016,’ highlights the pharmacological action of various therapeutics along with their history of research and development activities.

Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=873474

The report starts with a discussion about the vaginal atrophy disease. It is thinning, drying and inflammation of the vaginal walls due to the body having less estrogen and also known as atrophic vaginitis. It afflicts nearly 90% of women after menopause. For many women, vaginal atrophy not only makes intercourse painful, but also leads to distressing urinary symptoms. Some of the symptoms include-

•    Vaginal dryness
•    Itching
•    Burning with urination
•    Urinary tract infections
•    Urinary incontinence

Risk factors includes smoking because it affects the blood circulation and also reduces the naturally occurring estrogens in body. The guide further provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Women's Health) with complete analysis by stage of development, monotherapy products, drug target, mechanism of action (MoA), route of administration and molecule type. Major treatment includes: topical (vaginal) estrogen and systemic estrogen therapy. Also, researchers are working to develop other treatments because of concerns about the long-term potential for even small doses of estrogen to increase the risk of endometrial and breast cancer. Women who cannot use estrogen may use a water-soluble vaginal lubricant as needed to relieve vaginal dryness and moisten tissue.

Some of the drug profiles mentioned in the report includes, Lasofoxifene tartrate, Oxycin, Prasterone, WC-3011 and others. These drug profiles undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with latest information. With many new drugs in the pipeline, the market is expected to grow smoothly in the coming years.

In the next section, guide also reviews key companies along with their major and minor projects. The list of companies involved in therapeutics development for Vaginal Atrophy includes:

•    Ligand Pharmaceuticals, Inc.
•    Allergan Plc
•    EndoCeutics, Inc.
•    PEPTONIC medical AB
•    Foamix Pharmaceuticals Ltd.
•    Mithra Pharmaceuticals S.A.

Browse Full Report with TOC: http://www.marketresearchhub.com/report/vaginal-atrophy-atrophic-vaginitis-pipeline-review-h2-2016-report.html

The report enhances decision making capabilities of the reader and also help to create effective counter strategies for gaining competitive advantage. It also strengthens R&D pipelines by identifying new targets and MOA’s to produce best-in-class products.

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com